Date: 2016-09-22
Type of information: Collaboration agreement
Compound: new selective modulators of RhoB functions
Company: Evotec (Germany) Inserm Transfert (France)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism: modulator of RhoB function. RhoB is an oncological target implicated in the control of cellular stress response, migration, tumour neovascularisation and progression.
Disease:
Details: * On September 22, 2016, Evotec announced that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (“Inserm”). This collaboration with Inserm marks the initiation of the first project under Evotec’s and Sanofi’s Academic Bridge, which was established as a result of the multi-component strategic alliance between the companies effective 01 April 2015. This Academic Bridge aims to accelerate the translation of promising cutting-edge science from French academic institutions into pharmaceutical product candidates. In this joint effort, Evotec scouts and incubates projects generated in France under its EVT Innovate strategy.
A year after initiating the French Academic Bridge, the first collaboration between Evotec and Prof. Gilles Favre’s team from Inserm/the Université Toulouse III – Paul Sabatier/Oncopole de Toulouse has started. The research collaboration’s goal is to characterise and develop new selective modulators of RhoB functions as a promising approach to increase therapeutic options in many cancers with high unmet medical need.
Financial terms:
Latest news:
